SMB 23/4/15

SMB 23/4/15

SMB 23/4/15

SMB 23/4/15

1Finer LB et al. Contraception 2011;84:478-85

SMB 23/4/15

1Singh S et al. Stud Fam Plann 2010;41:241-50

SMB 23/4/15

Trussell J. Contraception 2011;83:397–404

PPR

LARC

SMB 23/4/15

Author IUD/IUS Expulsion Removal bleeding/pain

Continuation rate (1 year)

Paterson et al. Questionnaire

Mirena 8 ? 85

Suhonen et al. RCT vs OCs

Mirena 1.2 20 79.8

Teal et al. Retrospective

Paragard/ Mirena

16.7/13.3 18.2/22.7 (B/P) 55

Brockm. et al. Prospective

Copper Mirena

7 17 (?) 65

Garbers et al Retrosp (6 months)

Paragard/ Mirena

4,2 11 74.5 (6 months)

Berensen et al. Large retrospective

Paragard/ Mirena

? 32.8/19.7 (15-19)

32.0/21.5 (20-24)

79.8/88.2 (15-19)

84.1/87.7 (20-24)

Rasheed et al. Prospective (6 months)

Paragard

10 41.7 58.3

SMB 23/4/15

Museum M. Thiery, PAND, Ghent, Belgium

SMB 23/4/15

Hasson HM. Philadelphia: Harper & Row, 1984: 126-141

SMB 23/4/15

32 mm 32 mm 28 mm 2.5 mm

Uterus too wide for IUD/S

Uterus too narrow for IUD/S

SMB 23/4/15

GynNext

SMB 23/4/15

SMB 23/4/15

SMB 23/4/15

SMB 23/4/15

GynNext develops with the patient in mind

Contraceptives

Pill Mirena Nuvaring

Implanon IUD Depoprovera

Non-Hormonaal

Less Expulsion

Post abortion

Reversible Sterilisation

Nulli-pare / Intra Partum

Better Geometry

Meeting patient needs Problem solving

GynNext benefits vs competitor Drives substitution

IUB

IUS

IUD

3

12.5

SMB 23/4/15

GynNext HQ

“GynNext Local”

Local doctors

Website &

Logistics

Building Circles

& Day to day

contact FAQ

MS & Medical support

GynNext products can be offered best to the community via a limited number of specialized and well instructed centers located in the most populated areas

Building local presence

SMB 23/4/15

SMB 23/4/15

1/10 2/10 10/10

Volume

Capacity

Future Volume

SMB 23/4/15